Login to Your Account

From $16M Net to $1B Opportunity

Progenics Picks Salix Sales of Relistor in Potential $350M Deal

By Tom Wall

Tuesday, February 8, 2011
If at first you don't succeed . . . Progenics Pharmaceuticals Inc. licensed rights to Relistor (methylnaltrexone bromide), its opioid-induced constipation (OIC) drug for patients with advanced disease, to Salix Pharmaceuticals Ltd. in a deal potentially worth $350 million or more.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription